DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Wednesday, 13 May 2015

Susan Heavey

Postdoctoral Researcher at Trinity College Dublin

Ireland

https://ie.linkedin.com/pub/susan-heavey/40/624/7a9

Summary

She is a postdoctoral researcher in the Department of Surgery at Trinity College Dublin. My key interests are: targeted therapies, signalling pathways in cancer, biomarker identification & validation, resistance to cancer therapies, personalized medicine and translational research.

Education

Trinity College, Dublin

Postgraduate Diploma, Statistics

2012 – 2013

In depth modules covering statistical analysis, regression and design & analysis of experiments

Trinity College, Dublin

BA (Mod), Molecular Medicine

2007 – 2011

Thesis entitled: Investigating Mechanisms of Resistance to Cancer Therapies
Major modules included molecular oncology, immunology, biochemistry, molecular biology, medicinal chemistry and statistics.

(Open)2 honors and awards

Loreto Abbey Dalkey

2001 – 2007

Experience

Postdoctoral Researcher

Trinity College Dublin

January 2015 – Present (5 months)Department of Surgery

Project title: Understanding the role of cancer stem-like cells in resistance to radiation using a clinically-relevant model of radioresistance in oesophageal adenocarcinoma.

Postdoctoral Researcher

Trinity College Dublin

October 2014 – October 2014 (1 month)Department of Clinical Medicine

Project title: Targeting a novel kinase in lung cancer.

Funding: Enterprise Ireland & Inflection Bioscience (one month feasibility study).

Techniques: FACS, apoptosis & proliferation assays, phosphoprotein profiling.

PhD candidate

Trinity College Dublin

October 2011 – September 2014 (3 years)Institute of Molecular Medicine, Trinity Centre, St. James Hospital

Project Title: Identification of biomarkers of response & resistance to PI3K targeted inhibition in NSCLC.

Funding: Irish Cancer Society Scholarship (Grant code CRS11HEA).

Research Areas: PI3K & related pathway mutation status in NSCLC patient samples, targeted and co-targeted inhibition of the PI3K pathway in NSCLC, strategies for inhibiting the PI3K-NFκB axis in cisplatin resistant NSCLC, development and characterisation of a panel of PI3K-mTOR dual inhibitor resistant NSCLC cell lines.

Techniques: Cell culture, SDS-PAGE, Western blot, RTPCR, QPCR, gene expression arrays, phosphoprotein expression arrays, BrdU proliferation assays, ELISA, High Content Analysis (HCA), Multiparameter apoptosis assays, DNA sequencing, miRNA expression profiling, clonogenic assays, irradiation, immunofluorescence, drug combination studies, FACS, hypoxia studies, densitometry, statistical analysis.

Intern - Thoracic Oncology

Trinity College Dublin

June 2011 – September 2011 (4 months)Institute of Molecular Medicine, Trinity Centre, St. James Hospital

Internship in the Thoracic Oncology Research Group, conducting further investigation into data generated during my final year research project.

Research area: Cisplatin Resistance in Non Small Cell Lung Cancer

Techniques: Cell Culture, RTPCR, Western Blot, High Content Analysis,

Intern - Immunology

Case Western Reserve University

July 2010 – September 2010 (3 months)Centre for Global Health and Disease, CWRU

Internship in the Hise laboratory at the Centre for Global Health & Disease.

Research area: The immune response to Rift Valley Fever Virus.

Techniques: Cell culture, Transfections, Molecular Cloning, DNA Isolation, ELISA, Dissections and Lymphocyte Isolation.

Publications

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.(Link)

Cancer Biology & Therapy

July 15, 2014

Chemoresistance is a major therapeutic challenge to overcome in NSCLC, in order to improve the current survival rates of<15% at 5 years. We and others have shown increased PI3K signaling in NSCLC to be associated with a more aggressive disease, and a poorer prognosis. In this study, targeted inhibition of three strategic points of the PI3K-NFκB axis was performed with the aim of exploiting...more-

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.(Link)

Cancer Treatment Review

August 26, 2013

The PI3K/AKT/mTOR pathway regulates cell growth and proliferation and is often dysregulated in cancer due to mutation, amplification, deletion, methylation and post-translational modifications. We and others have shown that activation of this pathway in non-small cell lung cancer (NSCLC) leads to a more aggressive disease which correlates to poor prognosis for patients. A multitude of selective...more

3 authors

Chapter 7: Targeted Therapies in Non-Small Cell Lung Cancer(Link)

Lung Cancer: A Comprehensive Overview (Kathy Gately, Nova Publishers)

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.(Link)

Front Oncol.

2013

Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy. Front. Oncol. doi: 10.3389/fonc.2013.00120.

Honors & Awards

Poster Prize (Translational Medicine category)

9th International Cancer Conference

September 2014

Title of Poster: In depth molecular characterisation of a novel panel of PI3K-mTOR inhibitor resistant NSCLC cell lines.

Scholar-in-training Award

American Association for Cancer Research

August 2014

Scholar-in-Training Award supported by Aflac, Inc. to support my attendance at the AACR Special Conference on Targeting the PI3K-mTOR Network in Cancer, being held from September 14–17, 2014 in Philadelphia, PA, USA.

Travel Award

European Society for Medical Oncology

January 2014

ESMO Travel Award to attend the ESMO Symposium on Signalling Pathways in Cancer 2014:Targeting the PI3K/AKT/mTOR pathway.

Finalist: Cell Imaging Competition

GE Healthcare

November 2013

Finalist in the 2013 cell imaging competition, with my image being shown in Times Square, NYC. https://www.youtube.com/watch?v=4LlpabzT7Wk

Poster Prize (Basic Science Category)

British Thoracic Oncology Group Annual Conference

January 2012

Title of Poster: NFκB-IκBα Interaction: a Mechanism of Resistance to Cisplatin in NSCLC.

Cancer Research Ireland Scholarship

Irish Cancer Society Research

October 2011

Title of grant: The Identification of Biomarkers that Predict Sensitivity/Resistance to PI3K Inhibitors.

Highly Commended (Medical Science Category)

Undergraduate Awards of Ireland and Northern Ireland

July 2011

Title of Paper: IκBα - a Mechanism of Resistance to Cisplatin in NSCLC

Margaret Ciotti Medal

TCD School of Biochemistry and Immunology

May 2011

Award for highest marked undergraduate thesis in the School of Biochemistry. Title of Thesis: Investigating Mechanisms of Resistance to Cancer Therapies